Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.

ABSTRACT:

Objective

Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma (TC).

Methods

We pooled data from three phase I/II larotrectinib clinical trials (NCT02576431, NCT02122913, and NCT02637687). The primary endpoint was the investigator-assessed objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors v1.1. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Data cut-off: July 2020.

Results

Twenty-nine patients (median age: 60; range: 6-80) with TRK fusion-positive TC were

SUBMITTER: Waguespack SG 

PROVIDER: S-EPMC9066591 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature